Polymorphisms in solute carrier genes ( <scp> SLC19A1 </scp> , <scp> SLCO1B1 </scp> , and <scp> SLCO1B3 </scp> ) predicts survival and toxicity in North Indian lung cancer patients undergoing platinum‐based doublet chemotherapy-Reference-Cited by-同舟云学术

Polymorphisms in solute carrier genes ( SLC19A1 , SLCO1B1 , and SLCO1B3 ) predicts survival and toxicity in North Indian lung cancer patients undergoing platinum‐based doublet chemotherapy

Published:2022-07-27 Issue:12 Volume:47 Page:2049-2067
ISSN:0269-4727
Container-title:Journal of Clinical Pharmacy and Therapeutics
language:en
Short-container-title:Clinical Pharmacy Therapeu

Author:

Sharma Parul¹,Singh Navneet²,Sharma Siddharth¹^ORCID

Affiliation:

1. Department of Biotechnology Thapar Institute of Engineering & Technology Patiala India

2. Department of Pulmonary medicine Post Graduate Institute of Medical Education & Research Chandigarh India

Publisher

Hindawi Limited

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcpt.13748

Reference49 articles.

1. Cancer statistics, 2020

2. Thymidylate synthase polymorphisms are associated to therapeutic outcome of advanced non-small cell lung cancer patients treated with platinum-based chemotherapy

3. Genetic Variations of Drug Transporters Can Influence on Drug Response in Patients Treated with Docetaxel Chemotherapy

4. Modulation of OATP1B-Type Transporter Function Alters Cellular Uptake and Disposition of Platinum Chemotherapeutics

5. SLC transporters as therapeutic targets: emerging opportunities

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Based on disulfidptosis-related glycolytic genes to construct a signature for predicting prognosis and immune infiltration analysis of hepatocellular carcinoma;Frontiers in Immunology;2023-08-23